Claims for Patent: 6,645,496

Summary for Patent: 6,645,496

Title:	Method for treating tardive dyskinesia with Botulinum toxin type B
Abstract:	A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s):	Aoki; K. Roger (Laguna Hill, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee:	Allergan Sales, Inc. (Irvine, CA)
Application Number:	09/796,068
Patent Claims:	1. A method for treating tardive dyskinesia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B in order to treat tardive dyskinesia. 2. The method of claim 1, wherein the botulinum toxin type B is administered by intramuscular injection. 3. The method of claim 1, wherein the administration of the botulinum toxin type B results in an alleviation of a symptom of the tardive dyskinesia within about 1 day to about 3 days. 4. The method of claim 1, wherein the patient is administered at least about 50 units of the botulinum toxin type B. 5. The method of claim 1, wherein the patient is administered at least about 1,000 units of the botulinum toxin type B. 6. A method for treating tardive dyskinesia, the method comprising the step of administration to a human patient of an effective amount of botulinum toxin type B, the administration of the botulinum toxin type B resulting in an alleviation of a symptom of the tardive dyskinesia within about 1 day to about 3 days and the patient is administered at least about 1,000 units of the botulinum toxin type B. 7. A method for treating tardive dyskinesia or dystonia the method comprising the step of intramuscular or subcutaneous administration to a human patient of an effective amount of a botulinum toxin type B, the administration of the botulinum toxin type B resulting in an alleviation of a symptom of the tardive dyskinesia or the dystonia within about 1 day to about 3 days, and the patient is administered at least about 1,000 units of the botulinum toxin type B. 8. A method for treating a condition selected from the group consisting of orofacial dyskinesia, athetosis, dystonia, chorea, tics and facial grimacing by administration to a human patient of an effective amount of a botulinum toxin type B.

Details for Patent 6,645,496

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2013-12-28